Clinical Trial Update: Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating long-term safety and tolerability of PXT3003 in Charcot-Marie-Tooth disease type 1A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Charcot-marie-tooth Disease Type 1a

Drugs mentioned

• PXT3003

Snippet

Sponsor: Pharnext S.C.A. | Conditions: Charcot-Marie-Tooth Disease, Type IA | Phase 3 | Status: UNKNOWN